[{"Assets_0_Q2_USD":1556600000.0,"CommonStockSharesOutstanding_0_Q2_shares":73200000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":45600000.0,"NetIncomeLoss_1_Q2_USD":2600000.0,"NetIncomeLoss_2_Q2_USD":1900000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":74200000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":73600000.0,"StockholdersEquity_0_Q2_USD":1064200000.0,"EarningsPerShareBasic_1_Q2_USD":0.04,"EarningsPerShareBasic_2_Q2_USD":0.03,"Ticker":"MYGN","CIK":"899923","name":"MYRIAD GENETICS INC","OfficialName":"Myriad Genetics Inc. Common Stock","form":"10-Q","period":"20181231","fy":"2019.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1850258412.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20190206"}]